Roche joins EMBL’s Corporate Partnership Programme

On June 12, 2018, Posted by , In News, By ,, , With Comments Off on Roche joins EMBL’s Corporate Partnership Programme

Roche and EMBL join forces to create new training opportunities for young researchers                               EMBL welcomes Roche, a frontrunner in personalised healthcare and leading provider of in vitro diagnostics, to the EMBL Advanced Training Centre Corporate Partnership Programme. The new partners will develop advanced training for young investigators and the…

BioMed X and Merck extend research collaboration in oncology

On May 8, 2018, Posted by , In News, By ,, , With Comments Off on BioMed X and Merck extend research collaboration in oncology

BioMed X announced the start of a new research project in collaboration with Merck at its Innovation Center in Heidelberg. The new team will focus on the identification of novel approaches to exploit tumor-specific RNA splicing alterations for targeted cancer therapy.     Dr. Jan Mauer, who joined the BioMed X…

Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

On May 4, 2018, Posted by , In News, By , , With Comments Off on Affimed Introduces ROCK™ Platform for Tailored Immune Cell Engagers

Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced the official launch of its Redirected Optimized Cell Killing (ROCK™) platform. Based on the company’s long-standing expertise in drug development and protein engineering, the ROCK™ platform enables the generation of both NK…

Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

On March 21, 2018, Posted by , In News, By , , With Comments Off on Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met…

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

On March 20, 2018, Posted by , In News, By ,, , With Comments Off on Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Boehringer Ingelheim and Vanderbilt University announced the expansion of their successful existing collaboration to develop novel anti-cancer compounds. The expanded research partnership will focus on the discovery and development of new chemical therapeutics targeting the pro-survival protein MCL1 as a potential therapy against MCL1 dependent cancers. This is the third…

Sciomics: Solving Alzheimers with this company’s new approach?

On March 14, 2018, Posted by , In News, By , , With Comments Off on Sciomics: Solving Alzheimers with this company’s new approach?

Labiotech.eu media recently profiled our member Sciomics, a German Cancer Research Center (DKFZ) spin-off founded in 2013 by a team of researchers led by Dr. Christoph Schröder and Dr. Jörg Hoheisel. Sciomics has developed antibody microarrays as a tool for analyzing complex protein samples. Using their expertise, they are able to address…

BioMed X and Roche announce research collaboration in the field of immunology

On March 13, 2018, Posted by , In News, By , , With Comments Off on BioMed X and Roche announce research collaboration in the field of immunology

BioMed X announced today the initiation of a new research collaboration with F. Hoffmann-La Roche Ltd in the field of immunology. Within the framework of the agreement, BioMed X will launch a global call for applications to establish a new biomedical research group in Heidelberg. The main objective of the…

New EMBL spinoff company Velabs Therapeutics to accelerate antibody discovery

On March 8, 2018, Posted by , In News, By , , With Comments Off on New EMBL spinoff company Velabs Therapeutics to accelerate antibody discovery

An established proprietary microfluidics technology from the European Molecular Biology Laboratory (EMBL) allows for fast screening of antibodies from natural sources and even difficult targets. With the startup company Velabs Therapeutics, launched by EMBL and its technology transfer arm EMBLEM Technology Transfer GmbH (EMBLEM) together with private investors, the advantages…

GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

On March 6, 2018, Posted by , In News, By , , With Comments Off on GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

GSK today announced new data published in The Lancet Child & Adolescent Health from a Phase III clinical trial with Fluarix Tetra (inactivated quadrivalent influenza vaccine [IIV4]) which prevented influenza A and B in children six to 35 months of age. Vaccine efficacy was highest against moderate-to-severe influenza, where the…